The 25% decline in Centene’s stock seems warranted given the substantial earnings adjustment and ongoing ambiguity. With more state data still forthcoming and the threat of additional earnings ...

CNBC’s Jim Cramer gave his take Centene and the broader health insurance space after shares plummeted on Wednesday.

Centene is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings drop.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

U.S. equities mostly gained at midday on a new U.S.-Vietnam trade agreement, although the advance was limited by a decline in ...

Shares of Centene are experiencing a historic collapse this week. Wednesday marked the worst single-day performance in the company's history.

After its stock price closed at $56.65 on Tuesday, Centene announced that afternoon it was scrapping its 2025 guidance, triggering an after-hours sell off.

The significant downgrade comes as UBS revised its earnings per share estimates for Centene, projecting a 55% decline to $3.25 for 2025 and a 45% decline to $4.50 for 2026.

CNBC's Jim Cramer offered his take on Centene and the broader health insurance space as its stock plummeted when management unexpectedly withdrew full-year guidance.